211 related articles for article (PubMed ID: 23253000)
21. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
23. [Pulmonary hypertension treatment: future prospects].
Baloira A
Arch Bronconeumol; 2007 Mar; 43(3):131-5. PubMed ID: 17386188
[No Abstract] [Full Text] [Related]
24. Acute and long-term efficacy and safety of sildenafil for the treatment of chronic thromboembolic pulmonary hypertension in a heart transplant recipient.
Zacà V; Padeletti M; Pagliaro A; Furiozzi F; Mondillo S; Favilli R
Pharmacology; 2011; 87(1-2):24-7. PubMed ID: 21178386
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
Kähler CM; Graziadei I; Vogelsinger H; Desole S; Cima K; Vogel W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):248-52. PubMed ID: 21451953
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Hoeper MM
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
[TBL] [Abstract][Full Text] [Related]
27. Endothelin receptor antagonists-induced hepatotoxicity.
Macías Saint-Gerons D; de la Fuente Honrubia C; Montero D; Catalá-López F
Intern Med J; 2013 May; 43(5):609-10. PubMed ID: 23668280
[No Abstract] [Full Text] [Related]
28. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
Wilkins MR
Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
[No Abstract] [Full Text] [Related]
29. [Pulmonary arterial hypertension related to systemic sclerosis in 2008].
Agard C; Haloun A; Hamidou MA
J Mal Vasc; 2009 Feb; 34(1):7-15. PubMed ID: 19081217
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
[TBL] [Abstract][Full Text] [Related]
31. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Shetty N; Derk CT
Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
[TBL] [Abstract][Full Text] [Related]
32. Sildenafil improves clinical and functional status of an elderly postmenopausal female with 'out of proportion' PH associated with left heart disease.
Correale M; Totaro A; Ferraretti A; Di Biase M; Brunetti ND
Monaldi Arch Chest Dis; 2013 Dec; 80(4):193-4. PubMed ID: 25087297
[TBL] [Abstract][Full Text] [Related]
33. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects.
Stavros F; Kramer WG; Wilkins MR
Br J Clin Pharmacol; 2010 Jan; 69(1):23-6. PubMed ID: 20078609
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil.
Koumakis E; Wipff J; Kahan A; Allanore Y
Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S53-4. PubMed ID: 20576215
[TBL] [Abstract][Full Text] [Related]
35. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
Mittoo S; Jacob T; Craig A; Bshouty Z
Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
[TBL] [Abstract][Full Text] [Related]
36. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.
Humpl T; Reyes JT; Erickson S; Armano R; Holtby H; Adatia I
Cardiol Young; 2011 Apr; 21(2):187-93. PubMed ID: 21138617
[TBL] [Abstract][Full Text] [Related]
37. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Owen K; Cross DM; Derzi M; Horsley E; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289
[TBL] [Abstract][Full Text] [Related]
38. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
Minniti CP; Machado RF; Coles WA; Sachdev V; Gladwin MT; Kato GJ
Br J Haematol; 2009 Dec; 147(5):737-43. PubMed ID: 19775299
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Moinzadeh P; Hunzelmann N; Krieg T
J Am Acad Dermatol; 2011 Sep; 65(3):e102-e104. PubMed ID: 21839301
[No Abstract] [Full Text] [Related]
40. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S
Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
